Semaglutide | CAS 910463-68-2

Product Details

CasNo： 910463-68-2

Product Overview

Semaglutide, CAS 910463-68-2, is a 31-amino-acid lipidated peptide analog derived from the human GLP-1(7-37) sequence.

Its molecular design combines Aib8 and Arg34 substitutions with site-specific lipidation at Lys26, where a hydrophilic linker connects the peptide backbone to a C18 fatty diacid. This defined modification pattern makes Semaglutide relevant to GLP-1 receptor research, lipidated peptide studies, peptide characterization, and analytical method development. 

Shandong Juntai Pharmaceutical supports B2B R&D projects involving Semaglutide, GLP-1-related peptides, lipidated peptide structures, and related peptide-synthesis building blocks.

Product Information

Product Features

Defined GLP-1(7-37)-Based Peptide Structure

Semaglutide retains a GLP-1-related 31-amino-acid peptide backbone while incorporating specific structural changes at positions 8, 26, and 34.

The Aib8 and Arg34 substitutions are part of the defined peptide identity, while Lys26 serves as the attachment site for the lipidated side chain. These structural elements should be considered together when confirming material identity or comparing Semaglutide-related peptide structures. 

Site-Specific Lipidation at Lys26

A key feature of Semaglutide is the side-chain modification attached to Lys26.

The side chain includes a hydrophilic linker and a C18 fatty diacid, forming a characteristic lipidated peptide architecture. For R&D and sourcing teams, the attachment site, linker structure, and long-chain lipid component are important parameters when evaluating Semaglutide or related intermediates. 

More Than an HPLC Purity Number

For a structurally modified peptide, HPLC purity alone does not fully establish product identity.

A more complete analytical evaluation may include:

• HPLC purity
• Molecular-weight verification
• MS / LC-MS identity
• Peptide backbone confirmation
• Lipid side-chain characterization
• Modification-site confirmation
• Related impurity profiling

This approach is particularly useful for comparing batches, evaluating synthetic routes, or establishing project-specific analytical requirements.

Research Applications

GLP-1 Receptor Research

Semaglutide is relevant to GLP-1 receptor (GLP-1R) research, including ligand–receptor interaction, receptor pharmacology, signaling studies, and comparative GLP-1 analog research.

Experimental results should be interpreted within the specific assay model and research system used.

Lipidated Peptide and Linker Research

The Lys26-linked side chain makes Semaglutide a useful reference structure for research involving:

• Site-specific peptide lipidation
• Fatty-acid-modified peptides
• Peptide linker systems
• Peptide–albumin interaction studies
• Modified lysine building blocks
• Structure–function relationships

The linker and C18-derived long-chain structure are especially relevant to peptide synthesis and process-development research.

Peptide Structure and Analytical Characterization

Semaglutide may also be used in:

• HPLC method development
• LC-MS characterization
• Molecular-weight confirmation
• Modified peptide identity testing
• Lipidation-related structural analysis
• Related impurity studies

These applications are relevant to peptide R&D, analytical development, and process-development teams.

Custom Support

Shandong Juntai Pharmaceutical supports Semaglutide-related and other lipidated peptide projects according to the target structure and analytical requirements.

Project discussions may include:

• GLP-1-related peptide sequences
• Non-natural amino-acid incorporation
• Aib-containing peptides
• Site-specific lipidation
• Fatty diacid and linker modifications
• Modified lysine building blocks
• Target purity requirements
• HPLC / MS / LC-MS analysis
• Project-specific quantities and packaging

Juntai's current portfolio also includes peptide side-chain building blocks relevant to lipidated peptide research, including Fmoc-L-Lys[Oct-(OtBu)-Glu-(OtBu)-AEEA-AEEA]-OH (CAS 1662688-20-1), AEEA-AEEA (CAS 1143516-05-5), and Octadecanedioic Acid Mono-tert-butyl Ester (CAS 843666-40-0). These materials represent different structural stages and should be selected according to the intended synthesis route. 

Frequently Asked Questions

What should be confirmed when sourcing Semaglutide for an R&D project?

Beyond CAS 910463-68-2, buyers should confirm the required purity, molecular identity, lipidated structure, analytical documentation, quantity, and packaging requirements before quotation.

Can batch-specific COA, HPLC, or MS / LC-MS documentation be provided?

Relevant documentation can be reviewed according to the actual supply batch. If your project requires specific identity, purity, molecular-weight, or modification-related data, please include these requirements with your inquiry.

What are the MOQ, packaging options, and lead time?

These depend on the requested quantity, specification, packaging format, and current project arrangement. Small R&D quantities and larger B2B requirements can be evaluated separately.

Can higher purity or project-specific analytical criteria be requested?

Yes. Target purity, related impurities, HPLC, MS / LC-MS, and other analytical requirements can be evaluated based on the project.

Does Juntai support Semaglutide-related intermediates and building blocks?

Yes. Juntai supplies several linker, long-chain, and lipidated lysine building blocks associated with peptide side-chain research. Because these intermediates represent different structural and protection states, the exact CAS number and intended role in the synthesis route should be confirmed before sourcing. 

For research and development use only.